2022-05-31
The European Patent Office intends to grant a Patent for Selection Algorithm
NextCell Pharma AB ("NextCell" or the "Company") today announces that the European Patent Office (EPO) has issued an Intention to Grant notice relating to the patent entitled "Allogeneic Composition" (publication number EP3752598). The patent describes the method of manufacturing the drug candidat P
Read moreRead more2022-05-24
NextCell invited to speak at Advance Therapies Congress in London
NextCell Pharma AB (“NextCell”) present the ongoing clinical trial program with the lead cell therapy drug candidate, ProTrans, at the Advanced Therapies Congress in London on May 24th-25th. The presentation will be given by NextCell’s CEO, Dr. Mathias Svahn on Wednesday.
Read moreRead more2022-04-28
NextCell Pharma publishes Interim Report 2 2021/2022
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2021 – February 28, 2022 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth M
Read moreRead more2022-04-26
NextCell is attending a conference for worldleading celltherapies
NextCell Pharma AB ("NextCell" or the"Company") is attending the International Society for Cell and Gene Therapy 2022 in San Francisco, May 4-7. The company is represented by Mathias Svahn, CEO who is a member of the Business Development and Finance Committee will participate in workshops, round t
Read moreRead more2022-04-07
First age group treated in paediatric diabetes study with ProTrans
NextCell Pharma AB ("NextCell") today announces that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years.
Read moreRead more2022-04-01
Cellaviva delivers stem cells to treat serious blood disease
NextCell Pharma AB ("NextCell" or the ”Company”) announces that the stem cell bank Cellaviva has released umbilical cord blood stem cells to Rigshospitalet, Denmark's leading hospital.
Read moreRead more2022-02-22
The Canadian ProTrans in COVID-19 single center trial is expanded to a multicenter trial
NextCell Pharma AB (“NextCell”) today announces that the clinical trial ProTrans19+CA expanded to include an additional site: the Jewish General Hospital in Montreal, Canada. The hospital is one of the largest in Canada and is affiliated with the trial Sponsor, the Research Institute of McGill University Health Center. Patient enrolment increased due to the omicron variant, which we envisage will be further enhanced by patient reqruitment at both sites, the Royal Victoria and Jewish General Hospital.
The coronavirus pandemic has transformed over time and omicron has shown to be more
NextCell Pharma AB (“NextCell”) today announces that the clinical trial ProTrans19+CA expanded to include an additional site: the Jewish General Hospital in Montreal, Canada. The hospital is one of the largest in Canada and is affiliated with the trial Sponsor, the Research Institute of McGill U...
Read moreRead more2022-02-21
Pediatric diabetes study with ProTrans in progress
NextCell Pharma AB ("NextCell") has previously announced a clinical trial with ProTrans™ to treat children and adolescents with type 1 diabetes. The study recently started with screening of patients. Before treatment, patients are followed for about a month and the first adolescents will soon undergo treatment.
The first part of the study is a safety part (phase Ib) where all patients are treated at Akademiska university hospital. 3 patients aged 12-18 years receive treatment first and there after 3 patients aged 7-11 years. The data will then be reviewed by the Data Safety Monitoring Board,
NextCell Pharma AB ("NextCell") has previously announced a clinical trial with ProTrans™ to treat children and adolescents with type 1 diabetes. The study recently started with screening of patients. Before treatment, patients are followed for about a month and the first adolescents will soon und...
Read moreRead more